News & Announcements

The category, in motion.

Partnership announcements, standard revisions, scientific milestones, and category developments from Opticeuticals and Atumnus Life Sciences.

See the category →Media inquiries →

Red tulips in clear glass vases — editorial stillness

Partnership

April 8, 2026

Activation Products and Atumnus Life Sciences Announce Formulation Collaboration for the Opticeutical Category

Activation Products founder Ian Clark joins Atumnus Life Sciences as Founding Curator. The two organizations begin formal collaboration on peptide-class bioregulator formulations developed under the Opticeutical Standard.

Read →

Intellectual Property

March 4, 2026

The Delivery Platform Portfolio: Trade-Named, Patent-Pending Across the Full Stack

An overview, at the level publicly statable during ongoing prosecution, of the trade-named delivery platform portfolio and the IP architecture beneath the Opticeutical category.

Read →

Standard

February 18, 2026

The Opticeutical Standard: Six Pillars, Published in Full

The published six-pillar standard governing what may bear the Opticeutical designation — composition rigor, bioavailability, mechanism rationale, third-party verification, manufacturing discipline, sourcing integrity. No partial qualification.

Read →

Category Launch

February 15, 2026

Opticeuticals: A Category, Defined and Published

The naming, the definition, and the published category authority for optimized nutraceuticals. The fourth stage in the supplement evolution, now formally named and stewarded.

Read →

Research

November 8, 2025

Bioelectric Regeneration: Extending the Endogenic Framework Beyond Peptide Signalling

An expansion of the endogenic framework to incorporate the bioelectric signalling layer characterised by the Levin laboratory and the broader morphogenesis field. The seven-layer integrative model and what it means for the category.

Read →

Cross-Application

September 30, 2025

The Veterinary Frontier: Cross-Species Evidence for the Bioregulator Framework

Veterinary applications of peptide-class bioregulator compounds are not a side project for the Atumnus program — they are an essential cross-species validation surface for the underlying framework. A working note on what the BovineEmbryonics program is doing and what it indicates for the broader category.

Read →

Clinical Channel

August 26, 2025

The Clinical Channel and the 503A Pharmacy Distinction: Where Bioregulator Compounds Fit

The dietary supplement framework and the 503A compounding pharmacy framework are distinct regulatory tracks serving distinct purposes. A reading of where peptide-class bioregulator compounds fit in each, and how the Opticeutical category is structured to operate within the supplement track without conflicting with the clinical track that pharmacies and prescribers occupy.

Read →

Industry Analysis

July 22, 2025

The Longevity Category Landscape: Where Opticeuticals Sits Relative to the Other Attempts

Elysium Health, ProHealth Longevity, DoNotAge, NOVOS, Tally Health, Life Extension, Thorne, and the broader longevity supplement landscape. A reading of where each programme sits, what each is built around, and where the Opticeutical category is structurally distinct from any of them.

Read →

AI & Research

April 30, 2025

AI in Longevity Research: Where Machine Intelligence Helps, and Where It Cannot

The 2025 Scripps Research study on AI-driven longevity compound discovery has reset expectations for what machine intelligence can contribute to aging research. A reading of where AI helps, where it cannot, and what the HI-Centric-AI architecture is built to do.

Read →

Manufacturing

January 22, 2025

Manufacturing Under the Opticeutical Standard: What cGMP-Plus Actually Means

A practical working note for contract manufacturers, formulators, and brand owners considering qualification under the Opticeutical Standard. What the standard adds to cGMP, where the additional discipline applies, and what partners can expect from the qualification process.

Read →

Formulation Technical

November 12, 2024

Therapeutic Salts: The Carrier Chemistry Beneath the Opticeutical Category

Short-chain peptide formulation requires carrier chemistry that conventional pharmaceutical excipients do not adequately provide. A technical note on therapeutic salts as the formulation backbone of the Opticeutical category, and the design logic behind the Opti-Salt™ carrier family.

Read →

Regulatory Reading

October 25, 2024

DSHEA at Thirty: The Supplement Framework That Built an Industry, and What It Did Not Anticipate

The Dietary Supplement Health and Education Act, passed in 1994, is the framework that built the modern supplement industry. At thirty, a reading of what it did, what it did not anticipate, and how a category-level standard like the Opticeutical Standard operates within it.

Read →

Longevity Reading

August 14, 2024

What the Blueprint Protocol Gets Right, and What Comes Next

Bryan Johnson's Blueprint protocol has popularised a particular discipline of longevity intervention — the highly instrumented, protocol-stacked, biomarker-driven approach. A reading of what this discipline gets right, and what peptide-class regulatory compounds add that protocol stacking on its own cannot.

Read →

Mechanism Comparison

June 18, 2024

GLP-1 Spillover: Where Pathway Override Ends, and Endogenous Regulation Begins

Semaglutide, tirzepatide, and the broader GLP-1 era have reset consumer expectations for metabolic intervention. A reading of where pathway-override drugs reach their limits, and where peptide-class regulatory compounds operate relative to the GLP-1 mechanism.

Read →

Mechanism Comparison

December 4, 2023

The Hallmarks of Aging, 2023 Update: Where Peptide-Class Bioregulators Fit in the Map

The January 2023 Cell update to the Hallmarks of Aging framework is the most authoritative current map of cellular aging. A reading of where peptide-class bioregulator compounds sit relative to the named hallmarks, including the role of glycation in protein damage.

Read →

Industry Analysis

September 19, 2023

The Supplement Industry Quality Crisis: A Reading From Inside the Category

A decade of independent testing on dietary supplements has documented a quality variance the industry has not been able to close from within. A reading of the data, the structural causes, and why category-level standards are the only response that matches the problem.

Read →

Mechanism Comparison

August 30, 2023

The NAD+ Ceiling: Where NMN and NR Supplementation Plateaus, and What Lies Beyond

Why the NAD+ supplementation category — NMN, NR, and adjacent precursors — encounters a mechanistic ceiling, and how peptide-class bioregulator compounds sit upstream of the pathway it targets.

Read →

Founding

June 12, 2023

Atumnus Life Sciences: A Bioregulator IP Company Introduces Itself

The company that has spent four years quietly building the IP portfolio, the AI architecture, and the published standard behind the Opticeutical category introduces itself.

Read →

Research

August 22, 2022

Forty Years at the Bench: The Culmination of Eastern European Bioregulator Research

Four decades, eight hundred publications, and a research lineage that quietly outlasted three regulatory environments and one Soviet collapse. A reading of the bioregulator research culmination and why translation into consumer hands is appropriate now.

Read →

Heritage

March 14, 2022

The Codex of Legacy: A Note on Endogenic Medicine in the Pre-Pharmacology Era

Before the pharmaceutical industry existed as a category, the practitioners who understood the body best worked with the body's own regulatory chemistry. A short reading of the long tradition that bioregulator research now formalizes.

Read →

While You Wait

The foundations are published.

Definition

The category, in motion.

Activation Products and Atumnus Life Sciences Announce Formulation Collaboration for the Opticeutical Category

The Delivery Platform Portfolio: Trade-Named, Patent-Pending Across the Full Stack

The Opticeutical Standard: Six Pillars, Published in Full

Opticeuticals: A Category, Defined and Published

Bioelectric Regeneration: Extending the Endogenic Framework Beyond Peptide Signalling

The Veterinary Frontier: Cross-Species Evidence for the Bioregulator Framework

The Clinical Channel and the 503A Pharmacy Distinction: Where Bioregulator Compounds Fit

The Longevity Category Landscape: Where Opticeuticals Sits Relative to the Other Attempts

AI in Longevity Research: Where Machine Intelligence Helps, and Where It Cannot

Manufacturing Under the Opticeutical Standard: What cGMP-Plus Actually Means

Therapeutic Salts: The Carrier Chemistry Beneath the Opticeutical Category

DSHEA at Thirty: The Supplement Framework That Built an Industry, and What It Did Not Anticipate

What the Blueprint Protocol Gets Right, and What Comes Next

GLP-1 Spillover: Where Pathway Override Ends, and Endogenous Regulation Begins

The Hallmarks of Aging, 2023 Update: Where Peptide-Class Bioregulators Fit in the Map

The Supplement Industry Quality Crisis: A Reading From Inside the Category

The NAD+ Ceiling: Where NMN and NR Supplementation Plateaus, and What Lies Beyond

Atumnus Life Sciences: A Bioregulator IP Company Introduces Itself

Forty Years at the Bench: The Culmination of Eastern European Bioregulator Research

The Codex of Legacy: A Note on Endogenic Medicine in the Pre-Pharmacology Era

The foundations are published.

The Standard

Evolution

About